Kirk Christopher J. 4
4 · Kezar Life Sciences, Inc. · Filed Jun 27, 2022
Insider Transaction Report
Form 4
Kirk Christopher J.
DirectorCEO
Transactions
- Exercise/Conversion
Employee Stock Option (right to buy)
2022-06-23−33,060→ 123,361 totalExercise: $0.90Exp: 2025-09-09→ Common Stock (33,060 underlying) - Exercise/Conversion
Common Stock
2022-06-23$0.90/sh+33,060$29,754→ 381,484 total
Footnotes (2)
- [F1]Total reflects 1,953, 981, 986, 951 and 944 shares of common stock acquired on May 15, 2020, November 15, 2020, May 15, 2021, November 15, 2021 and May 15, 2022, respectively, through the Company's 2018 Employee Stock Purchase Plan.
- [F2]Fully vested and exercisable.